DNA was also subjected to NGS using the Colon and Lung Cancer Research panel, which allows the assessment of the mutational status of additional genes including DDR2, MAP2K1 and FBX7, which are not covered by the Cancer Hotspot panel. This evidence concerns the gene MAP2K1 and lung carcinoma.